(LMAT) LeMaitre Vascular - Ratings and Ratios

LeMaitre Vascular Inc. (NASDAQ:LMAT) is a leading developer, manufacturer, and marketer of medical devices and implants tailored for vascular surgery. The companys product portfolio addresses a wide array of vascular procedures, including peripheral bypass surgeries, dialysis access, and carotid endarterectomy. Their offerings include human cadaver tissue cryopreservation services, angioscopes for visualizing blood vessel interiors, and various catheters for embolectomy, thrombectomy, and perfusion. Additionally, they provide a range of biologic grafts and patches, such as Artegraft and XenoSure, used in vessel repair and reconstruction.

LeMaitres innovative products extend to biosynthetic vascular grafts for lower extremity bypass and dialysis access, and they offer unique solutions like radiopaque tape, which aids surgeons in locating subcutaneous structures. Their valvulotomes and closure systems using titanium clips enhance surgical efficiency. The companys strategic approach is evident in its direct sales force and distributor network, ensuring comprehensive market reach. Established in 1983 and renamed in 2001, LeMaitre is headquartered in Burlington, Massachusetts.

From an investment perspective, LeMaitre Vascular presents a compelling profile with a market capitalization of $2.17 billion, reflecting a P/E ratio of 53.26 and a forward P/E of 46.08. The price-to-book ratio stands at 6.80, and the price-to-sales ratio is 10.23, indicating a premium valuation. These metrics suggest a company positioned for growth, supported by a strong product pipeline and a solid financial foundation, making it an attractive consideration for investors and fund managers focusing on the medical device sector.